Guerbet SA

Detailed Description

Guerbet SA engages in the development and marketing of contrast media products, delivery systems, medical devices, and related solutions. The company offers Optiray and Xenetix, which are non-ionic monomeric and iodinated contrast agents; Telebrix Gastro, a meglumine ioxitalamate; Conray, an othalamate meglumine injection; and Micropaque/ Microtrast, a diagnostic imaging interconnected solution; Dotarem, a gadoteric acid-gadoterate meglumine, and Artirem products, as well as prefilled syringes, injectors, accessories, and consumables for MRI, CT, and Cath Lab. It also provides digital solutions, such as Contrast&Care, an injection management solution; Dose&Care, an X-ray dose management solution; and icobrain that offers cloud-based AI solutions, as well as OptiProtect services. In addition, the company provides products for interventional radiology, including Lipiodol ethyl esters of iodinated fatty acids of poppy seed oil; Vectorio, a mixing and injection system for conventional trans-arterial chemoembolization; Patent Blue V, an injectable medium; and SeQure and DraKon, which are microcatheters. Further, it offers Hydra Vision, a digital imaging system for urological, gastroenterological, and gynecological treatment, as well as planning and diagnostic procedures; and urology accessories and consumables. Guerbet SA was founded in 1926 and is headquartered in Villepinte, France.